biquinol for patients with multiple system atrophy
Not Applicable
- Conditions
- Patients with multiple system atrophy
- Registration Number
- JPRN-UMIN000010712
- Lead Sponsor
- Department of Neurology, the University of Tokyo Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1
Inclusion Criteria
Not provided
Exclusion Criteria
1. Subjects having received ubiquinone, ubiquinol, or idebenone 2. Subjects with severe liver dysfunction (Child-Pugh class A-C) 3. Female subjects who are pregnant, possibly pregnant, or nursing, or who plan to become pregnant during the trial period 4. Subjects who have received any investigational drug within 12 weeks prior to informed consent 5. Subjects who are determined as unfit for the study by attending physicians for reasons other than those stated above
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2. Coenzyme q10 levels in plasma, blood mononuclear cells, and cerebrospinal fluid 1. Adverse event
- Secondary Outcome Measures
Name Time Method 1. UMSARS Part II 2. Urinary 8-OHdG 3. Glucose metabolism of the cerebellum on FEG-PET 4. Oxygen metabolism of the cerebellum on 15O-PET